Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
US Stock Movement | Hims surges 55% pre-market, reaches licensing agreement with Novo Nordisk for weight loss medication
Gelonghui March 9 — According to sources, Novo Nordisk (NVO.US) and Hims & Hers Health Inc. (HIMS.US) are about to reach a settlement, with plans to announce a new partnership as early as Monday. The Danish pharmaceutical company will authorize the sale of its weight-loss drugs on the Hims platform, ending their public dispute. Boosted by this news, Hims’ stock price surged by 55% pre-market in the US, while Novo Nordisk rose about 1%. It is understood that the two parties reached a similar agreement last year, but Novo Nordisk unilaterally terminated the partnership after Hims refused to stop marketing generic drugs.